Decide at what price you'd be comfortable buying and we'll help you stay ready.
Abbott has generated positive free cash flow throughout the supplied annual history, with capital spending absorbing a minority of operating cash generation. Revenue growth has been uneven, and reported earnings have fluctuated more than cash generation.
The debt-funded Exact Sciences acquisition has enlarged the revenue base and balance-sheet commitments without a corresponding increase in trailing operating profit. The latest quarter's operating-margin recovery did not prevent lower earnings and free cash flow, making the cash available for debt reduction an important distinction from sales growth.
Whether free cash flow after dividends supports continued debt reduction without further depletion of cash balances.
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 20.9B | 27.4B | 30.6B | 31.9B | 34.6B | 43.1B | 43.7B | 40.1B | 42B | 44.3B | |
| (9.1B) | (12.4B) | (12.7B) | (13.2B) | (15B) | (18.5B) | (19.1B) | (17.9B) | (18.6B) | (19.2B) | |
| 11.8B | 15B | 17.9B | 18.7B | 19.6B | 24.6B | 24.6B | 22.2B | 23.3B | 25.1B | |
| (8.7B) | (13.1B) | (14.2B) | (14B) | (14.2B) | (16B) | (15.9B) | (15.5B) | (16.3B) | (16.8B) | |
| (6.7B) | (9B) | (9.7B) | (9.7B) | (9.7B) | (11.2B) | (11.1B) | (10.9B) | (11.7B) | (12.2B) | |
| (1.4B) | (2.2B) | (2.3B) | (2.4B) | (2.4B) | (2.7B) | (2.7B) | (2.6B) | (2.8B) | (2.9B) | |
| (550m) | (2B) | (2.2B) | (1.9B) | (2.1B) | (2B) | (2B) | (2B) | (1.9B) | (1.7B) | |
| 3.1B | 1.9B | 3.7B | 4.7B | 5.4B | 8.6B | 8.7B | 6.7B | 7B | 8.3B | |
| (827m) | (746m) | (749m) | (583m) | (492m) | (491m) | (377m) | (293m) | (188m) | (135m) | |
| 431m | 904m | 826m | 670m | 546m | 533m | 558m | 637m | 559m | 493m | |
| (32m) | (307m) | (247m) | (201m) | 42m | (163m) | (390m) | (283m) | (350m) | (274m) | |
| (786m) | 1.4B | 139m | 191m | (12m) | 277m | 366m | 518m | 558m | 548m | |
| 1.4B | 2.2B | 2.9B | 4.1B | 5B | 8.2B | 8.3B | 6.7B | 7B | 8.5B | |
| (350m) | (418m) | (409m) | (476m) | (471m) | (1.1B) | (1.4B) | (941m) | 6.4B | (1.9B) | |
| 1.1B | 1.8B | 2.5B | 3.6B | 4.5B | 7.1B | 6.9B | 5.7B | 13.4B | 6.5B | |
| 1.4B | 477m | 2.4B | 3.7B | 4.5B | 7.1B | 6.9B | 5.7B | 13.4B | 6.5B | |
| 0.94 | 0.27 | 1.33 | 2.07 | 2.52 | 3.95 | 3.93 | 3.27 | 7.67 | 3.73 |
Alpha Spread
Preferences
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
New to Alpha Spread? Create free account
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more